Ralph Wäsch
A5088238455- Multiple Myeloma Research and Treatments
- Acute Myeloid Leukemia Research
- Hematopoietic Stem Cell Transplantation
- Protein Degradation and Inhibitors
- Acute Lymphoblastic Leukemia research
- Peptidase Inhibition and Analysis
- Cancer Treatment and Pharmacology
- CAR-T cell therapy research
- Chronic Myeloid Leukemia Treatments
- Microtubule and mitosis dynamics
- Chronic Lymphocytic Leukemia Research
- Ubiquitin and proteasome pathways
- Histone Deacetylase Inhibitors Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Monoclonal and Polyclonal Antibodies Research
- Lymphoma Diagnosis and Treatment
- Immune Cell Function and Interaction
- Cancer-related Molecular Pathways
- T-cell and B-cell Immunology
- Childhood Cancer Survivors' Quality of Life
- Epigenetics and DNA Methylation
- Polyomavirus and related diseases
- Cancer Genomics and Diagnostics
- Lung Cancer Treatments and Mutations
University Medical Center Freiburg
2016-2025
University of Freiburg
2016-2025
Institut Curie
2023
Hudson Institute
2017
John Wiley & Sons (United States)
2017
University Medical Center
2011-2013
Palmetto Hematology Oncology
2011
Rockefeller University
2002-2003
Freie Universität Berlin
1995
PURPOSE Despite undergoing allogeneic hematopoietic stem cell transplantation (HCT), patients with acute myeloid leukemia (AML) internal tandem duplication mutation in the FMS-like tyrosine kinase 3 gene ( FLT3-ITD) have a poor prognosis, frequently relapse, and die as result of AML. It is currently unknown whether maintenance therapy using FLT3 inhibitors, such multitargeted inhibitor sorafenib, improves outcome after HCT. PATIENTS AND METHODS In randomized, placebo-controlled, double-blind...
With growing numbers of elderly multiple myeloma patients, reliable tools to assess their vulnerability are required. The objective the analysis herein was develop and validate an easy use risk score (revised Myeloma Comorbidity Index) that allows for prediction overall survival progression-free differences in a large patient cohort. We conducted comprehensive comorbidity, frailty disability evaluation 801 consecutive including comorbidity risks obtained at diagnosis. cohort examined within...
Multiple myeloma management has undergone profound changes in the past thanks to advances our understanding of disease biology and improvements treatment supportive care approaches. This article presents recommendations European Myeloma Network for newly diagnosed patients based on GRADE system level evidence. All with symptomatic should undergo risk stratification classify International Staging System stage (level evidence: 1A) cytogenetically defined high- versus standard-risk groups (2B)....
8003 Background: Tal is a T-cell redirecting bispecific antibody (BsAb) targeting G protein–coupled receptor family C group 5 member D. Dara an anti-CD38 mAb with direct on-tumor and immunomodulatory actions. Combining effects of tal + dara may lead to synergistic efficacy. Initial TRIMM-2 (NCT04108195) results showed that SC RP2Ds, 0.4 mg/kg QW or 0.8 Q2W, had promising efficacy increased CD38+/CD8+ T cells proinflammatory cytokines. We report updated additional pts longer follow-up....
This first validation of the International Myeloma Working Group geriatric assessment in 125 newly diagnosed multiple myeloma patients was performed using score based on age, Charlson Comorbidity Index and cognitive physical conditions (Activities Daily Living / Instrumental Activities Living) to classify as fit, intermediate-fit or frail. We verified score's impact outcome, whether additional tools complement it. Since our prior analyses determined renal, lung Karnofsky performance...
Abstract Bone marrow haematopoietic stem cells (HSCs) are vital for lifelong maintenance of healthy haematopoiesis. In inbred mice housed in gnotobiotic facilities, the top hierarchy is occupied by dormant HSCs, which reversibly exit quiescence during stress. Whether HSC dormancy exists humans remains debatable. Here, using single-cell RNA sequencing, we show a continuous landscape highly purified human bone HSCs displaying varying degrees dormancy. We identify orphan receptor GPRC5C,...
Despite recent advances in adapting the intensity of treatment for older patients with ALL, current protocols are associated high rates early deaths, treatment-related toxicity, and dismal prognosis. We evaluated inotuzumab ozogamicin dexamethasone (Dex) as induction therapy ALL within German Multicenter Study Group Adult (GMALL).
Comorbidities have been demonstrated to affect progression-free survival (PFS) and overall (OS), although their impact in multiple myeloma (MM) patients is as yet unsettled. We (1) assessed various comorbidities, (2) compared established comorbidity indices (CIs; Charlson index (CCI), hematopoietic cell transplantation-specific (HCT-CI)), Kaplan Feinstein (KF) Satariano (SI) (3) developed a MM-CI (Freiburger index, FCI) 127 MM patients. Univariate analysis determined moderate or severe...